Reimbursed Care Access in Peru

Currently classified among controlled psychotropic substances under national drug control listings with no authorized outpatient medical use or public reimbursement outside of formal clinical research. The national psychotropic controlled‑substance lists used by Peruvian authorities include psilocybin/psilocin among listed substances; there is no national regulatory approval or public‑insurance reimbursement policy for psilocybin‑assisted psychotherapy at present. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA (3,4‑methylenedioxymethamphetamine) appears on Peruvian national lists of controlled psychotropic substances, and there is no national licensing or public reimbursement pathway for MDMA‑assisted therapy. #.

Esketamine (Spravato) is registered for therapeutic use in Peru as a nasally administered medicinal product and is available through authorized medical import/distribution channels; its licensed indication aligns with treatment‑resistant depression paradigms used internationally (psychiatric specialist prescription, clinic administration, and observation). The product is shown in Peruvian pharmaceutical registries (example: SPRAVATO 28 mg nasal spray listed with a Peruvian registration number) and marketed by an authorized distributor, which permits controlled clinical use in private clinics under regulatory oversight — however, broad coverage by the public Seguro Integral de Salud (SIS) or Ministry of Health national reimbursement is not documented and access is typically through private providers or specialty psychiatric services. #.

Ketamine is an established, registered medicinal anesthetic and analgesic in Peru, included within national essential‑medicines/petitorio lists for hospital use and is procured for public and private health facilities via DIGEMID procurement/register mechanisms; approved uses include anesthesia, analgesia and other routine indications for which standard public procurement and hospital reimbursement apply. Off‑label psychiatric uses (off‑label ketamine infusions or ketamine‑assisted psychotherapy for depression) are practiced in private clinics and specialized centers; these psychiatric applications are generally provided outside universal public reimbursement frameworks (i.e., paid privately or billed through private insurers case‑by‑case) and are not standardized under a Ministry of Health national‑level reimbursement protocol. National procurement/essential medicines documents list ketamine among anesthetics used in public health settings. #, #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peruvian controlled‑substance lists include DMT (N,N‑dimethyltryptamine) among psychotropic substances subject to control; however, the legal treatment of plant preparations containing DMT (see Ayahuasca entry) differs due to cultural heritage protections. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. National lists explicitly control various tryptamine and psychotropic substances — synthetic isolates such as 5‑MeO‑DMT are treated under the country’s psychotropic controls and are not authorized for routine medical use or public reimbursement. #.

Currently classified as a strictly controlled or unapproved psychoactive substance with no authorized medical use in routine practice and no public reimbursement; clinical use would require special regulatory approval and is limited to formal, authorized research protocols if permitted. There is no documented national authorization, licensing framework, or reimbursement pathway for ibogaine‑assisted treatment in Peru. #.

Peru formally recognizes the traditional, ritual and medicinal use of ayahuasca and related indigenous practices and has declared the knowledge and traditional use of ayahuasca by Amazonian native communities to be part of the Cultural Heritage of the Nation (Resolución Directoral Nacional Nº 836/INC, 24 June 2008). This institutional recognition creates a legal/cultural protective framework that permits ritual/ceremonial preparation and use of ayahuasca in indigenous and traditional contexts and has been relied upon by the Ministry of Culture and other actors to differentiate traditional ceremonial use from decontextualized commercial uses; the protection does not amount to a pharmaceutical marketing authorization or a public reimbursement program for ayahuasca as a standardized medicinal product. Practically, ayahuasca is legally available in traditional/ceremonial settings (including regulated retreat centers and indigenous healing contexts) while isolated DMT (the pure chemical) remains controlled for general purposes under national psychotropic lists. #, #.

Mescaline as a purified chemical is listed among controlled psychotropic substances in national lists and therefore is not authorized for general medical prescribing or public reimbursement; nevertheless, certain psychoactive cacti that contain mescaline (e.g., San Pedro / Wachuma) are treated in Peruvian law and practice as part of traditional cultural medicines and ceremonial use of these plants is culturally protected, creating a practical distinction: extraction/sale/transport of pure mescaline is controlled, while traditional ceremonial use of cacti may be tolerated and culturally protected. In short: purified mescaline = controlled chemical (no routine medical reimbursement); ceremonial/traditional use of native cacti (Wachuma / San Pedro) = culturally protected traditional practice. #, #.

Currently classified as a strictly controlled substance (2C series and many substituted phenethylamines are included in national psychotropic/controlled‑substance lists) with no authorized medical use outside approved clinical research. There is no regulatory approval or reimbursement pathway for 2C‑class compounds in Peru. #.